Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients

Journal of Clinical Psychiatry

Volumn 58, Issue 7, 1997, Pages 318-322

  Spivak, Baruch ^a,d   Mester, Roberto ^a,d   Abesgaus, Joseph ^a   Wittenberg, Nathan ^b   Adlersberg, Simona ^a,d   Gonen, Noah ^a,d   Weizman, Abraham ^c,d  

^a NESS ZIONA MENTAL HEALTH CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; LEVODOPA; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INDICATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HAMILTON SCALE; HUMAN; MALE; NEGATIVE SYNDROME; PARKINSONISM; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0030792071     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v58n0706     Document Type: Article

References (42)

1. McCreadie RG, Robertson LG, Wiles DH. The Nithsdale schizophrenia surveys, IX: akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels. Br J Psychiatry 1992;161:793-799
2. Gerlach J, Peacock L. Intolerance to neuroleptic drugs: the art of avoiding extrapyramidal syndromes. European Psychiatry 1995;10(suppl 1):27-31
3. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994;55(9, suppl B):107-109
4. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544
5. Barnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985;42:874-878
6. Sachdev P. The epidemiology of drug-induced akathisia, II: chronic, tardive, and withdrawal akathisias. Schizophr Bull 1995;21:451-461
7. Woerner MG, Kane JM, Liberman JA. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991;11:34-42
8. Youssef HA, Waddington JL. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand 1987;75: 74-77
9. Safferman A, Lieberman JA, Kane JM, et al. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991;17:247-261
10. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55(9, suppl B):102-106
11. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 1989;99:47-53
12. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for Axis I DMS-IV Disorders, Patient Version (SCID-I/P, version 2.0). New York. NY: Biometric Research Department. New York State Psychiatric Institute; 1994
13. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
14. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia [letter]. Arch Gen Psychiatry 1982;39:486-487
15. Simpson G, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;45(suppl 212):11-19
16. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
17. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
19. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
20. Rey JM, Hunt GE, Johnson GFS. Assessment of tardive dyskinesia in psychiatric outpatients using a standardized rating scale. Aust N Z J Psychiatry 1981;15:33-37
21. Nader D, Leppig M, Grohman R, et al. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia: a retrospective study of 387 patients. Psychopharmacology (Berl) 1989; 99(suppl):S73-S76
22. Parsa M, Ramirez LF, Loula EC, et al. Effect of clozapine on psychotic depression and parkinsonism. J Clin Psychopharmacol 1991;11:330-331
23. Meltzer HJ, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190
24. Small JG, Milstein V, Marhenke JD, et al. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987;48:263-267
25. Lieberman JA, Johns CA, Cooper T, et al. Clozapine pharmacology and tardive dyskinesia. Psychopharmacology (Berl) 1989;99:54-59
26. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-510
27. Littrell K, Magill AM. The effect of clozapine on preexisting tardive dyskinesia. J Psychosoc Nurs 1993;31:14-18
28. Simpson G, Lee JM, Shrivastava RK. Clozapine in tardive dyskinesia. Psychopharmacology (Berl) 1978;56:75-80
29. Lamberty JS, Bellnier R. Clozapine and tardive dyskinesia. J Nerv Ment Dis 1993;181:137-138
30. Fleischhacker WW, Hummer M, Kunz M, et al. Clozapine dose in the United States and Europe: implication for therapeutic and adverse effects. J Clin Psychiatry 1994;55(9, suppl B):78-81
31. Povlsen UJ, Noring U, Fog R. Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 1985;71:176-185
32. Safferman AZ, Kane JM, Aronowitz JS, et al. The use of clozapine in neurologic disorders. J Clin Psychiatry 1994;55(9, suppl B):98-101
33. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986;73:295-297
34. Friedman JH, Lannen MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990;5:225-229
35. Fischer PA, Bass H, Hefner R. Treatment of parkinsonian tremor with clozapine. J Neural Transm 1990;2:233-238
36. Bennett JP, Landow ER, Schuch LA. Suppression of dyskinesia in advanced Parkinson's disease. Neurology 1993;43:1551-1555
37. Claghom J, Honigfeld G, Abuzzahab FS, et al. The risk and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987;7: 377-384
38. Cohen BM, Keck PE, Satlin A, et al. Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry 1991;29:1215-1219
39. Levin H, Chengappa KNR, Kambhampati RK, et al. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry 1992;53:248-251
40. 4 receptors in Parkinson's disease, schizophrenia, and control brain striata. Synapse 1993;14:247-253
41. Jeste DV, Wyatt RJ. In search of treatment for tardive dyskinesia: review of the literature. Schizophr Bull 1979;5:251-292
42. Bolden C, Cusack B, Richelson E. Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur J Pharmacol 1991;192:205-206